Search
What are you looking for?
Start main content

Press Releases

Press Releases

https://www.med.cuhk.edu.hk/press-releases/cu-medicine-uncovers-the-key-for-immune-suppression-in-lung-cancer-translating-blood-s-hidden-gem-neutrophil-into-a-new-generation-anti-cancer-therapy
https://www.med.cuhk.edu.hk/press-releases/cu-medicine-uncovers-the-key-for-immune-suppression-in-lung-cancer-translating-blood-s-hidden-gem-neutrophil-into-a-new-generation-anti-cancer-therapy

CU Medicine uncovers the key for immune suppression in lung cancer Translating blood’s hidden gem “Neutrophil” into a new generation anti-cancer therapy

Lung cancer remains the most common cancer in Hong Kong. As a leading cancer killer worldwide, its treatment still needs a breakthrough. Recent research from The Chinese University of Hong Kong (CUHK)’s Faculty of Medicine (CU Medicine) has discovered that neutrophils, the most abundant immune cell type in our blood, play a key role in lung cancer. The team successfully enhanced the anticancer capacity of human neutrophils with gene editing technology and confirmed their clinical potential on lung cancer animal models, suggesting them as the next generation immunotherapy that can overcome existing therapeutic barriers. Research results have been published in the leading international scientific journal Nature Communications.

 

According to the Hong Kong Cancer Registry, there are more than 5,000 new cases of lung cancer and about 4,000 related deaths in Hong Kong every year. Immunotherapy has begun to be applied to lung cancer in addition to the traditional chemotherapy and targeted therapy. However, checkpoint inhibitors, the most used immunotherapy in lung cancer, can only benefit 30% of lung cancer patients when used alone.  A better understanding of the uniqueness of the lung cancer microenvironment may shed new light on existing clinical dilemmas.      

Understanding immunodynamics in lung cancer is the key to resolve its clinical dilemma

 

Neutrophils are the most abundant white blood cells in our blood for defending microorganisms and viruses. However, their role in cancer is still unclear. Recent studies found that neutrophils are abundant in the microenvironment of lung cancer and closely related to cancer cell growth and drug resistance. It implies that there should be a not yet defined mechanism for suppressing the anti-cancer activity of neutrophils in the lung cancer microenvironment.

 

research team

(From left) Dr Herbert Loong, Associate Professor from the Department of Clinical Oncology; Professor To Ka-fai, Chairman; Professor Patrick Tang, Assistant Professor; and Dr Jeff Chung, Postdoctoral Fellow, from the Department of Anatomical and Cellular Pathology, at CU Medicine..

 

Professor Patrick Tang Ming-kuen, Assistant Professor from the Department of Anatomical and Cellular Pathology at CU Medicine, stated, “After neutrophils enter the tumour from blood, their roles and functions are dramatically changed due to the different microenvironment, leading to either anti-cancer N1 or pro-tumour N2 states with an unknown mechanism. The latest single-cell bioanalysis technology allows our team to investigate the dynamics and regulation of neutrophils in the lung cancer microenvironment, in order to identify an effective therapeutic strategy for enhancing patients’ anti-cancer immunity in clinic.”

 

The research team observed that neutrophils in lung cancer patients predominately exhibit the pro-tumour state, while those in anti-cancer form are rarely found. Dr Jeff Chung Yat-fai, Postdoctoral Fellow from the Department of Anatomical and Cellular Pathology at CU Medicine, explained, “Using single-cell RNA sequencing analysis, we unexpectedly found that neutrophils in the lung cancer microenvironment will first exhibit the pro-tumour state N2, then need further development to display their anti-cancer state N1. Our discovery breaks through the existing scientific knowledge.”

 

The first study translates neutrophils into a new generation immunotherapy for lung cancer

 

The team further used advanced bioinformatics to successfully identify an immune regulatory molecule Smad3 as the key for suppressing the anti-cancer capacity of neutrophils in the lung cancer microenvironment. They demonstrated that genetic deletion or drug inhibition of Smad3 in neutrophils can markedly increase N1 cells in tumour, thereby preventing lung cancer growth in mouse models.

 

Featured are gene-engineered anti-cancer neutrophils produced in laboratory.

Featured are gene-engineered anti-cancer neutrophils produced in laboratory.

Professor Patrick Tang, emphasised, “This is the first study to identify that Smad3 plays a key role in the immunosuppression of tumour-associated neutrophils, which means that the molecular regulatory mechanism of neutrophils can become an effective therapeutic target for lung cancer.”

 

Dr Herbert Loong Ho-fung, Associate Professor from the Department of Clinical Oncology at CU Medicine, opined, “In fact, neutrophils are innate immune cells that are easily obtained from our blood. Since neutrophil transplantation will not cause rejection, more patients can be benefited. Therefore, neutrophils are expected to overcome the clinical barriers of the current T cell immunotherapy. We look forward to seeing more breakthrough discoveries that will transform neutrophils into an effective and new clinical strategy for lung cancer.”

 

Professor To Ka-fai, Chairman of the Department of Anatomical and Cellular Pathology at CU Medicine, added, “Importantly, this study led to the first patented invention using gene engineering to mass produce anti-cancer neutrophils from human blood. They effectively inhibit human non-small cell lung carcinoma in vitro and in vivo, revealing the possibility of developing neutrophils into a novel immunotherapy. We hope to further translate our research discovery into a safe and effective new generation of immunotherapy for solid cancers.”

 

This study was supported by the Research Grants Council and CU Medicine’s “Passion for Perfection” scheme and Faculty Innovation Award. Other key participants in the study included Prof. David J. Nikolic-Paterson of Monash University, Postdoctoral Fellow Dr Philip Tang Chiu-tsun and PhD student Mr Max Chan Kam-kwan from CU Medicine.

 

The original study can be accessed here: https://www.nature.com/articles/s41467-023-37515-8.

 

More Press Releases

CUHK discovers a blood regulator linked to tumour microenvironment formation,  sparking a new therapeutic target for lung cancer

CUHK discovers a blood regulator linked to tumour microenvironment formation, sparking a new therapeutic target for lung cancer

Research
CUHK dissects lung carcinoma at single-cell resolution uncovering a new mechanism for tumour formation

CUHK dissects lung carcinoma at single-cell resolution uncovering a new mechanism for tumour formation

Research
CUHK Uncovers Novel Immune Escape Mechanism of Cancer Opening Up New Direction for Cancer Immunotherapy

CUHK Uncovers Novel Immune Escape Mechanism of Cancer Opening Up New Direction for Cancer Immunotherapy

Research
International lung cancer study involving CU Medicine shows that a targeted therapy doubles the progression-free survival of advanced cancer patients, compared to standard treatment

International lung cancer study involving CU Medicine shows that a targeted therapy doubles the progression-free survival of advanced cancer patients, compared to standard treatment

Research
CUHK unlocks the secret of cancer pain  Identifying a new therapeutic key to ending the sorrow

CUHK unlocks the secret of cancer pain Identifying a new therapeutic key to ending the sorrow

Research
CUHK Uncovers How Immune Cells Turn Bad A New Hope for Kidney Patients

CUHK Uncovers How Immune Cells Turn Bad A New Hope for Kidney Patients

Research
CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

Research
CU Medicine developed an innovative mRNA drug for treatment of nasopharyngeal carcinoma

CU Medicine developed an innovative mRNA drug for treatment of nasopharyngeal carcinoma

Research
International lung cancer study involving CU Medicine reveals that combination of immune drugs and chemotherapy represents new treatment regime for metastatic NSCLC patients

International lung cancer study involving CU Medicine reveals that combination of immune drugs and chemotherapy represents new treatment regime for metastatic NSCLC patients

Research
CUHK Uncovers a New Strategy to Turn “Cold” Liver Tumour “Hot” Leading to an Effective and Durable Combined Immunotherapy

CUHK Uncovers a New Strategy to Turn “Cold” Liver Tumour “Hot” Leading to an Effective and Durable Combined Immunotherapy

Research
Professor Tony Mok Recognised as a Giant of Cancer Care  for His Remarkable Contribution in Advancing Global Healthcare in Lung Cancer

Professor Tony Mok Recognised as a Giant of Cancer Care for His Remarkable Contribution in Advancing Global Healthcare in Lung Cancer

Awards and honors
CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

Research
CUHK Receives an International Cancer Care Team Award Nominated by Patients

CUHK Receives an International Cancer Care Team Award Nominated by Patients

Awards and honors
CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

Research
CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

Research
CUHK Joint Research Sets a New Global Direction for Lung Cancer Treatment Molecular Targeted Therapy Proved more Effective in Treating Patients with ALK-Positive Lung Cancer

CUHK Joint Research Sets a New Global Direction for Lung Cancer Treatment Molecular Targeted Therapy Proved more Effective in Treating Patients with ALK-Positive Lung Cancer

Research
CU Medicine combats resistance to immunotherapy in liver cancer

CU Medicine combats resistance to immunotherapy in liver cancer

Research
CUHK develops novel molecular classification of cancer-associated fibroblasts across multiple cancers, improving understanding for more targeted treatment

CUHK develops novel molecular classification of cancer-associated fibroblasts across multiple cancers, improving understanding for more targeted treatment

Research
CU Medicine establishes an internationally accredited biobank:  A prerequisite for Hong Kong to be the hub for new drug development in the Greater Bay Area

CU Medicine establishes an internationally accredited biobank: A prerequisite for Hong Kong to be the hub for new drug development in the Greater Bay Area

Milestone
CUHK performs world’s first robotic-assisted bronchoscopic  microwave ablation of lung metastases

CUHK performs world’s first robotic-assisted bronchoscopic microwave ablation of lung metastases

Surgical advancement
CUHK co-leads global lung cancer study  Supporting lorlatinib as first-line treatment option for ALK-positive advanced NSCLC patients

CUHK co-leads global lung cancer study Supporting lorlatinib as first-line treatment option for ALK-positive advanced NSCLC patients

Research
CUHK leading Asia’s battle to improve bile duct cancer survival rates by developing a novel combinational strategy in clinical trial

CUHK leading Asia’s battle to improve bile duct cancer survival rates by developing a novel combinational strategy in clinical trial

Research
Study by CUHK medical students identifies STK3 kinase as a driver in gastric cancer

Study by CUHK medical students identifies STK3 kinase as a driver in gastric cancer

Education
CU Medicine collaborates with South Korean institutes to develop  an AI-powered analytic tool for lung cancer immunotherapy

CU Medicine collaborates with South Korean institutes to develop an AI-powered analytic tool for lung cancer immunotherapy

Research
CUHK performs the first hybrid operating room robotic-assisted bronchoscopy procedure outside the US

CUHK performs the first hybrid operating room robotic-assisted bronchoscopy procedure outside the US

Surgical advancement
CU Medicine finds Eastern Asia’s lung cancer incidence and mortality highest in the world

CU Medicine finds Eastern Asia’s lung cancer incidence and mortality highest in the world

Research
CUHK study sheds light on novel mechanism and treatment of acute kidney injury in COVID-19 patients

CUHK study sheds light on novel mechanism and treatment of acute kidney injury in COVID-19 patients

Research
CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

Research
CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

Surgical advancement
Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Awards and honors
CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

Surgical advancement
A CUHK-led International Study Demonstrates Immune-checkpoint Inhibitor Is Effective in Patients with Advanced Nasopharyngeal Cancer

A CUHK-led International Study Demonstrates Immune-checkpoint Inhibitor Is Effective in Patients with Advanced Nasopharyngeal Cancer

Research
CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

Research
CUHK Research Receives Recognitions by Top Medical Journals

CUHK Research Receives Recognitions by Top Medical Journals

Awards and honors
CUHK Leads a Multinational Study that Finds New Treatment Paradigm of Mutated Lung Cancer

CUHK Leads a Multinational Study that Finds New Treatment Paradigm of Mutated Lung Cancer

Research
Inaugural Lecture of Li Shu Fan Medical Foundation Professorship in Clinical Oncology by Prof. Tony Mok 'Declaration of War Against Lung Cancer'

Inaugural Lecture of Li Shu Fan Medical Foundation Professorship in Clinical Oncology by Prof. Tony Mok 'Declaration of War Against Lung Cancer'

Symposium
CUHK Proves a Non-invasive Technology Can Successfully Cure Cerebral Arteriovenous Malformation

CUHK Proves a Non-invasive Technology Can Successfully Cure Cerebral Arteriovenous Malformation

Clinical service

Our Expert List

Many experts under the Faculty of Medicine are available for media interview.
Please click here for the expert list or contact us.